|Bid||16.80 x 800|
|Ask||16.92 x 800|
|Day's Range||16.08 - 17.49|
|52 Week Range||7.67 - 27.43|
|Beta (5Y Monthly)||2.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2022 - Oct 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.60|
Subscribe to Yahoo Finance Plus to view Fair Value for MYOV
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediatelyMyovant to host conference call and webcast on Monday, August 8, 2022, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time BASEL, Switzerland and NE
The big shareholder groups in Myovant Sciences Ltd. ( NYSE:MYOV ) have power over the company. Institutions will often...
At this time, I would like to turn the call over to Uneek Mehra, chief financial and business officer at Myovant. Joining me for today's call, are Dave Marek, Myovant's chief executive officer; Lauren Merendino, chief commercial officer; and Dr. Juan Camilo Arjona, chief medical officer.